This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS, The Journal of Clinical Endocrinology & Metabolism, October 2020, Endocrine Society,
DOI: 10.1210/clinem/dgaa756.
You can read the full text:
The following have contributed to this page
